| Dr Laura Ann Goguen, MD | |
|
111 Cypress St, Brookline, MA 02445-6002 | |
| (857) 307-0896 | |
| (617) 525-6511 |
| Full Name | Dr Laura Ann Goguen |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 34 Years |
| Location | 111 Cypress St, Brookline, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427036854 | NPI | - | NPPES |
| 179426 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 153621 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
| Dana-farber Cancer Institute, Inc. | 9133038904 | 538 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.
INTEGRA reports on how researchers at the renowned Forsyth Institute (Cambridge, MA) are using a VIAFLO Assist to enhance the efficiency while maintaining the accuracy of pipetting protocols related to the discovery, measurement, and validation of new biomarkers of disease that can be found in saliva.
Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.
Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.
› Verified 7 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.
INTEGRA reports on how researchers at the renowned Forsyth Institute (Cambridge, MA) are using a VIAFLO Assist to enhance the efficiency while maintaining the accuracy of pipetting protocols related to the discovery, measurement, and validation of new biomarkers of disease that can be found in saliva.
Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.
Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.
› Verified 7 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.
INTEGRA reports on how researchers at the renowned Forsyth Institute (Cambridge, MA) are using a VIAFLO Assist to enhance the efficiency while maintaining the accuracy of pipetting protocols related to the discovery, measurement, and validation of new biomarkers of disease that can be found in saliva.
Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.
Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura Ann Goguen, MD 47 Valley Rd, Wellesley, MA 02481-1445 Ph: (781) 431-2202 | Dr Laura Ann Goguen, MD 111 Cypress St, Brookline, MA 02445-6002 Ph: (857) 307-0896 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.
INTEGRA reports on how researchers at the renowned Forsyth Institute (Cambridge, MA) are using a VIAFLO Assist to enhance the efficiency while maintaining the accuracy of pipetting protocols related to the discovery, measurement, and validation of new biomarkers of disease that can be found in saliva.
Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has issued a notification of an intent to grant for the "Manoharan II" patent series (EP Application No 04 718 537), titled "Therapeutic Compositions." The new patent includes 16 claims covering compositions and methods, including pharmaceutical compositions, for chemically modified siRNAs containing phosphorothioate and 2′-O-alkyl modifications without any siRNA length restrictions.
Astellas Pharma Inc. announced today that the company has completed its acquisition of OSI Pharmaceuticals, Inc. for $4.0 billion.
› Verified 7 days ago
Dr. Bruce H Suzuki, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1 Brookline Pl, Suite 401, Brookline, MA 02445 Phone: 617-735-8855 Fax: 617-735-8864 | |
Douglas W Bell, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1 Brookline Pl, # S-401, Brookline, MA 02445 Phone: 617-735-8855 | |
Edwin Ishoo, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: One Brookline Place, Suite 321, Brookline, MA 02445 Phone: 781-552-6089 |